MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'corcept'. Sat, 03 Sep 2011 02:49:18 +0100 http://www.medworm.com/index.php?rid=4343331&cid=t_115341_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FMzN0NGIvnh4%2F In 2008, the US Senate Finance Committee charged that Stanford University failed to properly monitor alleged conflicts of interest involving Alan Schatzberg, the former chair of its psychiatry department, who owned a substantive amount of stock in Corcept Therapeutics, which was studying the development of mifepristone, or RU-486, for treating psychiatric depression. Beyond his stock holdings, Schatzberg was also listed as a co-patent holder for the drug, which is best known for inducing abortion, and he received a grant from the National Institutes of Health to oversee the research. The allegation was part of a lengthy probe into the wider issue of taxpayer-funded research and undisclosed and unmonitored conflicts involving universities, academic researchers and the pharmaceutical industr... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4343331 Thu, 13 Jan 2011 14:26:00 +0100 4343331 http://www.medworm.com/index.php?rid=1779680&cid=t_115341_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F386609971%2F For the first time since Stanford University last month reassigned his National Institutes of Health grant to another principal investigator (look here), the chair of the school’s psychiatry department is responding to the episode, which actually began earlier this year when the US Senate Finance Committee named him as an example of federally funded academics with conflicts of interest. You may recall that Schatzberg, who is also president-elect of the American Psychiatric Association, owns about $6 million in stock in Corcept Therapeutics, which is studying the development of mifepristone for treating psychotic depression. He is also a co-patent holder for the drug and he received an NIH grant to oversee the research. Stanford insisted he had no role in dealing with patients or anal... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1779680 Mon, 08 Sep 2008 11:50:15 +0100 1779680 http://www.medworm.com/index.php?rid=1686188&cid=t_115341_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2008%2F08%2Fcommercial-bias-at-stanford-and-corcept.html Stanford University has replaced Dr. Alan Schatzberg as Principal Investigator on his NIH grant that studies psychotic depression. This step followed persistent questions from Senator Grassley about conflicts of interest and financial disclosure. Dr. Schatzberg’s drug mifepristone has been in NIH-supported clinical trials at Stanford and in FDA-monitored trials sponsored by Corcept, the company Dr. Schatzberg founded.The University emphasized “We want to put to rest confusion about the integrity of the research involving mifepristone.” Questions did arise following NIH-supported publications from Stanford in 2001 and 2002. Neither one found significant evidence of efficacy, yet both were repeatedly touted by Dr. Schatzberg and his associates as positive. The 2001 report had no signif... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=1686188 Thu, 07 Aug 2008 04:48:00 +0100 1686188 http://www.medworm.com/index.php?rid=1674817&cid=t_115341_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2008%2F08%2Ffollow-money.html There is no sign of let-up in the scrutiny of Stanford University and Dr. Alan Schatzberg, who chairs the University’s department of psychiatry. Since Senator Grassley started asking questions last month, the explanations offered about Stanford’s management of this faculty member’s conflicts of interest vis à vis his NIH grants and his corporation (Corcept Therapeutics) have become non-viable. The story so far can be found here and here and here.Senator Grassley was concerned that Stanford gave him lowball information about Dr. Schatzberg’s financial stake in Corcept, and no information about Dr. Schatzberg’s realized financial gains from selling Corcept stock. Inspection of Stanford’s answers to Sen. Grassley and of the University’s faculty disclosure forms reveals that the... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=1674817 Fri, 01 Aug 2008 21:07:00 +0100 1674817 http://www.medworm.com/index.php?rid=1668704&cid=t_115341_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F350601005%2F Last month, the US Senate Finance Committee charged that Stanford University failed to properly monitor alleged conflicts of interest involving Alan Schatzberg, who chairs the psychiatry department and owns about $6 million in stock in Corcept Therapeutics, which is studying the development of mifepristone, or RU-486, for treating psychotic depression. In addition to his stock holdings, Schatzberg is also a co-patent holder for the drug, which is best known for inducing abortion, and he received a grant from the National Institutes of Health to oversee the research. In response to the charges that Schatzberg failed to properly disclose this tangled web, Stanford issued a statement defending Schatzberg by saying, among other things, that all conflicts were properly disclosed. Schatzberg &#8... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1668704 Wed, 30 Jul 2008 15:40:27 +0100 1668704 http://www.medworm.com/index.php?rid=1660748&cid=t_115341_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F348623650%2Filoperidone-vanda-shareholder-train.html Many months back, when shares of Vanda Pharmaceuticals were going for 29 bucks, I warned y'all: Their main product, iloperidone, showed all the signs of being a dud. It has been in the clinical trials stage of development for about a decade and it had yet to receive FDA approval. Um, if a drug was of significant benefit, do you really think it would have been in late-stage development for 10 years? In December 2006, I wrote: As for iloperidone, one article forecasted that it would hit the market in 2001! Further digging indicated that Titan, which holds the license for iloperidone (to some extent, anyway), was in a spot of trouble for allegedly hiding the drug’s side effect profile. In 1997, according to a report filed with the SEC, “the Company does not have the funds necessary to co... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=1660748 Mon, 28 Jul 2008 17:52:00 +0100 1660748 http://www.medworm.com/index.php?rid=1622086&cid=t_115341_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2008%2F07%2Fschatzberg-stanford-and-american.html 14 July 2008SCHATZBERG, STANFORD and the AMERICAN PSYCHIATRIC ASSOCIATIONThe chairman of psychiatry at Stanford University, Dr. Alan Schatzberg, is still in the news for his problems at the boundary of commerce and academia. The New York Times reported that Dr. Schatzberg believes constraints on researchers trying to develop drugs “will mean less opportunities to help patients with severe illnesses.” Just as patriotism is the last refuge of the scoundrel, so patient welfare is the last refuge of the dodgy medical entrepreneur.What exactly does Dr. Schatzberg mean by “constraints”? Does he object to transparency as a “constraint”? Would he feel “constrained” by the need to disclose his stock sales to his academic institution? The Stanford Daily commented recently that Stanfo... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=1622086 Mon, 14 Jul 2008 21:19:00 +0100 1622086 http://www.medworm.com/index.php?rid=1546655&cid=t_115341_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F320627759%2Fconflicts-bad-science-and-corlux.html Recently, the watchful eyes of Charles Grassley have been peering into the bank accounts of big name psychiatrists. Melissa DelBello and Joe Biederman (1, 2) from the Wonderful World of Child Bipolar were first, and now Alan Schatzberg has been hit. Schatzberg is the Chair of Psychiatry at Stanford University. He is also the President of the American Psychiatric Association. In other words, he's kind of a big deal. Pharmalot hits the details, but the gist is that Schatzberg is deeply involved at Corcept Therapeutics, a company for which he is chair of the scientific advisory board and holds a large amount of stock. According to Grassley, he did not disclose some of his stock sale profits or the magnitude of his multimillion dollar stock holdings in the company. Additionally, Schatzberg al... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=1546655 Thu, 26 Jun 2008 16:04:00 +0100 1546655